BioAge Labs (NASDAQ:BIOA) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of BioAge Labs (NASDAQ:BIOA) from a strong sell rating to a sell rating in a report issued on Sunday morning,Wall Street Zen reports.

Several other analysts have also issued reports on the company. BTIG Research restated a “buy” rating and issued a $40.00 price objective on shares of BioAge Labs in a research note on Tuesday, September 8th. Weiss Ratings reiterated a “sell (d-)” rating on shares of BioAge Labs in a research note on Tuesday, July 21st. Roth Capital reissued a “buy” rating and set a $25.00 target price on shares of BioAge Labs in a report on Wednesday, September 9th. Needham & Company LLC dropped their price target on BioAge Labs from $50.00 to $35.00 and set a “buy” rating on the stock in a research note on Friday, July 31st. Finally, Jefferies Financial Group set a $21.00 price target on BioAge Labs in a report on Friday, July 31st. Six investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $36.57.

BioAge Labs Price Performance

BioAge Labs stock opened at $8.18 on Friday. The company’s 50-day moving average is $14.28 and its 200-day moving average is $17.23. The firm has a market capitalization of $375.46 million, a PE ratio of -3.44 and a beta of 0.94. BioAge Labs has a fifty-two week low of $4.68 and a fifty-two week high of $25.95.

BioAge Labs (NASDAQ:BIOA) last issued its earnings results on Wednesday, August 5th. The company reported ($0.58) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.65) by $0.07. BioAge Labs had a negative net margin of 912.26% and a negative return on equity of 28.99%. The business had revenue of $2.45 million during the quarter. As a group, analysts expect that BioAge Labs will post -2.45 EPS for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in BIOA. Engineers Gate Manager LP acquired a new stake in shares of BioAge Labs in the second quarter valued at approximately $344,000. Squarepoint Ops LLC grew its position in BioAge Labs by 23.3% during the second quarter. Squarepoint Ops LLC now owns 68,436 shares of the company’s stock worth $1,677,000 after buying an additional 12,916 shares in the last quarter. Corient Private Wealth LP increased its stake in BioAge Labs by 76.7% during the 2nd quarter. Corient Private Wealth LP now owns 40,258 shares of the company’s stock worth $987,000 after acquiring an additional 17,476 shares during the period. Yiheng Capital Management L.P. bought a new position in BioAge Labs during the 2nd quarter worth $4,180,000. Finally, Wellington Management Group LLP raised its holdings in BioAge Labs by 39.9% in the 2nd quarter. Wellington Management Group LLP now owns 94,656 shares of the company’s stock valued at $2,320,000 after acquiring an additional 26,975 shares in the last quarter.

BioAge Labs Company Profile

BioAge Labs, Inc (NASDAQ:BIOA) is a clinical-stage biotechnology company focused on developing medicines that target the biological mechanisms of aging. Its research uses human longevity data and proprietary computational biology tools to identify pathways associated with aging-related diseases and to develop potential therapies aimed at extending healthy lifespan and improving physical function.

The company’s lead investigational program is azelaprag, also known as BGE-105, an oral small-molecule apelin receptor agonist being studied for its potential to preserve muscle mass and improve physical performance in older adults.